Although further studies of validation are indeed required, our study provided gender differences in blood EPAC1 levels and its diagnostic performance in CAD allowing to integrate a gender perspective into the future clinical application of this innovative biomarker. This evidence concerns the gene RAPGEF3 and coronary artery disorder.